- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody–Drug Conjugates for Cancer Therapy
Authors
Keywords
-
Journal
MOLECULES
Volume 25, Issue 20, Pages 4764
Publisher
MDPI AG
Online
2020-10-17
DOI
10.3390/molecules25204764
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.
- (2020) Andrew H. Ko et al. JOURNAL OF CLINICAL ONCOLOGY
- Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models
- (2020) Jianhua Gong et al. Artificial Cells Nanomedicine and Biotechnology
- ImmunoPET: Concept, Design, and Applications
- (2020) Weijun Wei et al. CHEMICAL REVIEWS
- SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.
- (2020) Amita Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.
- (2020) Melissa Lynne Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors.
- (2020) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors.
- (2020) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
- (2020) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Antibody–Drug Conjugate Design: Current Clinical Landscape and Future Innovations
- (2020) Laurence Gauzy-Lazo et al. SLAS Discovery
- ARX788, a Site-specific anti-HER2 Antibody Drug Conjugate, Demonstrates Potent and Selective Activity in HER2 Low and T-DM1 Resistant Breast and Gastric Cancers
- (2020) Lillian Skidmore et al. MOLECULAR CANCER THERAPEUTICS
- Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
- (2020) Mark G. Anderson et al. MOLECULAR CANCER THERAPEUTICS
- SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
- (2019) Chang-yong Yang et al. ACTA PHARMACOLOGICA SINICA
- Acquired Resistance to Antibody-Drug Conjugates
- (2019) Denis Collins et al. Cancers
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress
- (2019) Seiji Saito et al. PROTEIN SCIENCE
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
- (2019) Johann S de Bono et al. LANCET ONCOLOGY
- Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
- (2019) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma
- (2019) Rong Wang et al. CANCER LETTERS
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity
- (2019) Yijun Shen et al. mAbs
- MEN1309/OBT076, a first-in-class Antibody-drug Conjugate (ADC) targeting CD205 in solid tumors.
- (2019) Giuseppe Merlino et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies
- (2019) Nirav N. Shah et al. BLOOD
- Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)
- (2019) Tiziana Vaisitti et al. BLOOD
- A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- (2019) Brad S. Kahl et al. CLINICAL CANCER RESEARCH
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors
- (2019) Barbara Akla et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
- (2019) Francis W. Hunter et al. BRITISH JOURNAL OF CANCER
- San Antonio Breast Cancer Symposium 2019
- (2019) Katherine Gourd LANCET ONCOLOGY
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors
- (2019) Marco Gymnopoulos et al. Molecular Oncology
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE
- (2019) Jing Jiang et al. TOXICOLOGY LETTERS
- 46OA Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate
- (2018) A Tolcher et al. ANNALS OF ONCOLOGY
- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?
- (2018) RG Morgan et al. BRITISH JOURNAL OF CANCER
- Resistance to Antibody–Drug Conjugates
- (2018) Sara García-Alonso et al. CANCER RESEARCH
- Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies
- (2018) Lawrence L'Italien et al. CLINICAL CANCER RESEARCH
- Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
- (2018) Umbreen Hafeez et al. CURRENT OPINION IN PHARMACOLOGY
- A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer
- (2018) Kathleen N Moore et al. Future Oncology
- Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
- (2018) Anastasios Stathis et al. INVESTIGATIONAL NEW DRUGS
- Fate of Antibody-Drug Conjugates in Cancer Cells
- (2018) Cécile Chalouni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas
- (2018) Rong Wang et al. Molecular Oncology
- Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models
- (2018) Lei Kang et al. MOLECULAR PHARMACEUTICS
- Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of Its Identified Metabolite
- (2018) Josh T. Snyder et al. MOLECULAR PHARMACEUTICS
- Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody–Drug Conjugates
- (2018) Ali Azhdarinia et al. MOLECULAR PHARMACEUTICS
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody–Drug Conjugates
- (2018) Eshita Khera et al. BIODRUGS
- Abstract 820: Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer
- (2018) Juniper A. Scribner et al. CANCER RESEARCH
- Abstract 835: TRPH-222, a novel anti-CD22 antibody drug conjugate (ADC), has significant anti-tumor activity in NHL xenografts and reduces B cells in monkeys
- (2018) Ann P. Maclaren et al. CANCER RESEARCH
- Abstract 1782: Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer
- (2018) Xiaofan Li et al. CANCER RESEARCH
- Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC
- (2018) Louise A. Koopman et al. CANCER RESEARCH
- A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.
- (2018) Jordi Rodon Ahnert et al. JOURNAL OF CLINICAL ONCOLOGY
- PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.
- (2018) Jasgit C. Sachdev et al. JOURNAL OF CLINICAL ONCOLOGY
- MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity
- (2018) Xin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
- (2018) Steven Horwitz et al. LANCET
- MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
- (2017) J. Goldman et al. Journal of Thoracic Oncology
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
- (2017) Yu-Jie Wang et al. Marine Drugs
- Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
- (2017) Matthew Sung et al. MOLECULAR CANCER THERAPEUTICS
- Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
- (2017) Hao Chen et al. MOLECULES
- Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
- (2017) Muhammad Kalim et al. Drug Design Development and Therapy
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
- (2017) Courtney Davis et al. BMJ-British Medical Journal
- Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
- (2017) Hagop M Kantarjian et al. Lancet Haematology
- Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
- (2017) Ricarda M. Hoffmann et al. OncoImmunology
- Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM).
- (2017) J. G. Berdeja et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
- (2016) Lydia Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
- (2016) F. Li et al. CANCER RESEARCH
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding
- (2016) Rami N Al-Rohil et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
- (2016) Xing Gong et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of Resistance to Antibody–Drug Conjugates
- (2016) Frank Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1
- (2016) Simon-Peter Williams et al. Oncotarget
- Covalent Bonding of Pyrrolobenzodiazepines (PBDs) to Terminal Guanine Residues within Duplex and Hairpin DNA Fragments
- (2016) Julia Mantaj et al. PLoS One
- Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
- (2015) G. Gebhart et al. ANNALS OF ONCOLOGY
- ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
- (2015) L. E. Lamberts et al. CLINICAL CANCER RESEARCH
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Antibody-targeted drugs and drug resistance—Challenges and solutions
- (2015) LeeRon Shefet-Carasso et al. DRUG RESISTANCE UPDATES
- Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products
- (2015) Matthew Trendowski DRUGS
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of action of therapeutic antibodies for cancer
- (2015) J.M. Redman et al. MOLECULAR IMMUNOLOGY
- Antibody Conjugates with Unnatural Amino Acids
- (2015) Trevor J. Hallam et al. MOLECULAR PHARMACEUTICS
- Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
- (2015) Ronald C. Elgersma et al. MOLECULAR PHARMACEUTICS
- Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies
- (2015) Qing-long Guo et al. Drug Design Development and Therapy
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
- (2014) S. M. Horwitz et al. BLOOD
- Trastuzumab emtansine: mechanisms of action and drug resistance
- (2014) Mark Barok et al. BREAST CANCER RESEARCH
- Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
- (2014) Johanna Bendell et al. CANCER RESEARCH
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
- (2014) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models
- (2014) Kathleen R Whiteman et al. mAbs
- Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
- (2014) S. A. M. Urru et al. Drugs in research & development
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
- (2013) J. Deckert et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
- (2013) G. D. L. Phillips et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates: current status and future directions
- (2013) Heidi L. Perez et al. DRUG DISCOVERY TODAY
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients
- (2012) E. L. Servais et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin
- (2012) Nina D. Wagner-Johnston et al. LEUKEMIA & LYMPHOMA
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Site-specific chemical protein conjugation using genetically encoded aldehyde tags
- (2012) David Rabuka et al. Nature Protocols
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
- (2010) Y. V. Kovtun et al. CANCER RESEARCH
- Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
- (2010) K I Kaitin et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Stability of IgG isotypes in serum
- (2010) Ivan Correia mAbs
- Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines
- (2010) Barbara Gerratana MEDICINAL RESEARCH REVIEWS
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
- (2010) M. Lopus et al. MOLECULAR CANCER THERAPEUTICS
- Antibody–drug conjugates for cancer: poised to deliver?
- (2010) Bethan Hughes NATURE REVIEWS DRUG DISCOVERY
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Phase I Biodistribution and Pharmacokinetic Study of Lewis Y-Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial Cancers
- (2009) R. A. Herbertson et al. CLINICAL CANCER RESEARCH
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML
- (2009) Petra Haag et al. EXPERIMENTAL HEMATOLOGY
- Site specific protein labeling by enzymatic posttranslational modification
- (2009) Murat Sunbul et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
- (2008) Jagath R. Junutula et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now